

Dabigatran: Review of Pharmacology and Management Novel Oral Anticoagulant

Journal of Medical Toxicology

7, 281-287

DOI: [10.1007/s13181-011-0178-y](https://doi.org/10.1007/s13181-011-0178-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Disorders of the pulmonary circulation. <i>Current Opinion in Pulmonary Medicine</i> , 2011, 17, 379.	1.2	1
2	Pharmacological basis and clinical evidence of dabigatran therapy. <i>Journal of Hematology and Oncology</i> , 2011, 4, 53.	6.9	15
3	Disorders of the pulmonary circulation. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 391-392.	1.2	0
4	Neurosurgical complications of direct thrombin inhibitorsâ€™ catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. <i>Journal of Neurosurgery</i> , 2012, 116, 1093-1096.	0.9	95
5	Rectal Bleeding and Hemostatic Disorders Induced by Dabigatran Etxilate in 2 Elderly Patients. <i>Annals of Pharmacotherapy</i> , 2012, 46, e14-e14.	0.9	32
6	Is Dabigatran Cost Effective Compared With Warfarin for Stroke Prevention in Atrial Fibrillation?. <i>Neurologist</i> , 2012, 18, 102-107.	0.4	17
7	Management of dabigatran-induced anticoagulation in trauma and acute care surgery patients. <i>Journal of Trauma and Acute Care Surgery</i> , 2012, 73, 1064-1069.	1.1	10
8	Epidural Hematoma and Intraoperative Hemorrhage in a Spine Trauma Patient on Pradaxa (Dabigatran). <i>Spine</i> , 2012, 37, E863-E865.	1.0	48
9	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2011. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2012, 26, 3-10.	0.6	9
10	New direct oral anticoagulants â€™ current therapeutic options and treatment recommendations for bleeding complications. <i>Thrombosis and Haemostasis</i> , 2012, 108, 625-632.	1.8	64
11	Trends in the management of atrial fibrillation: A neurologist's perspective. <i>Journal of Cardiovascular Disease Research (discontinued)</i> , 2012, 3, 255-264.	0.1	5
13	Anti-stroke prophylaxis â€™ the ethics of collateral damage. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 792-794.	0.8	8
14	Blood component support in acquired coagulopathic conditions: Is there a method to the madness?. <i>American Journal of Hematology</i> , 2012, 87, S56-62.	2.0	15
16	New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials. <i>Clinical Therapeutics</i> , 2012, 34, 894-901.	1.1	38
17	Dabigatran Excess: Case Report and Review of the Literature. <i>Cardiology and Therapy</i> , 2013, 2, 111-124.	1.1	8
18	New Oral Anticoagulants in Non-Valvular Atrial Fibrillation. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 53-60.	1.0	3
19	Contemporary Anticoagulation Reversal. <i>Journal of Pharmacy Practice</i> , 2013, 26, 43-51.	0.5	6
20	Review of Recently Approved Alternatives to Anticoagulation with Warfarin for Emergency Clinicians. <i>Journal of Emergency Medicine</i> , 2013, 45, 143-149.	0.3	15

#	ARTICLE	IF	CITATIONS
21	Fatality in a patient treated with dabigatran. American Journal of Emergency Medicine, 2013, 31, 443.e1-443.e2.	0.7	7
22	Moving Toward a More Ideal Anticoagulant. Chest, 2013, 143, 1106-1116.	0.4	28
23	Hemorrhagic Complications in Emergency Department Patients Who Are Receiving Dabigatran Compared With Warfarin. Annals of Emergency Medicine, 2013, 61, 475-479.	0.3	42
24	Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding: A Single Center Experience. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1533-1539.	2.2	91
25	Novel oral anticoagulants in gastroenterology practice. Gastrointestinal Endoscopy, 2013, 78, 227-239.	0.5	94
26	Alternatives to Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Look Back at the State of the Field in 2012. Postgraduate Medicine, 2013, 125, 146-157.	0.9	0
27	Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients. American Journal of Clinical Pathology, 2013, 140, 610-622.	0.4	18
28	Gastrointestinal bleeding with the new oral anticoagulants “defining the issues and the management strategies. Thrombosis and Haemostasis, 2013, 110, 205-212.	1.8	155
29	Drug Interactions between Non-Steroidal Anti-Inflammatory Drugs and Cardiovascular Treatments (Except Anti-Agregant Therapy). Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12, 36-46.	1.1	3
30	Massive haemoptysis following dabigatran administration in a patient with bronchiectasis. BMJ Case Reports, 2014, 2014, bcr2013201001-bcr2013201001.	0.2	2
31	Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: A Sonoclot in vitro study. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 591-598.	0.6	10
32	Hemostasis and Anticoagulants. , 2014, , 479-496.		3
33	Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. Clinical Toxicology, 2014, 52, 283-287.	0.8	17
34	Epistaxis and Dabigatran, a New Non-Vitamin K Antagonist Oral Anticoagulant. Acta Otorrinolaringologica (English Edition), 2014, 65, 346-354.	0.1	5
35	Emergency surgery and trauma in patients treated with the new oral anticoagulants. Journal of Trauma and Acute Care Surgery, 2014, 77, 486-494.	1.1	14
36	Epistaxis y dabigatr�n, nuevo anticoagulante oral no antagonista de la vitamina K. Acta Otorrinolaringol�gica Espa�ola, 2014, 65, 346-354.	0.2	16
37	Targeting the GPIIb/3 Binding Site of Thrombin To Simultaneously Induce Dual Anticoagulant and Antiplatelet Effects. Journal of Medicinal Chemistry, 2014, 57, 3030-3039.	2.9	22
38	Emergency Reversal of Anticoagulation: Novel Agents. Current Neurology and Neuroscience Reports, 2014, 14, 471.	2.0	13

#	ARTICLE	IF	CITATIONS
39	Management of Antithrombotic Agents in Oral Surgery Maria Martinez and Dimitrios A. Tsakiris *. Dentistry Journal, 2015, 3, 93-101.	0.9	6
40	Anticoagulation Drug Therapy: A Review. Western Journal of Emergency Medicine, 2015, 16, 11-17.	0.6	184
41	New oral anti-coagulants: Implications for neurosurgery. British Journal of Neurosurgery, 2015, 29, 182-188.	0.4	2
42	Benzimidazoles and benzoxazoles via the nucleophilic addition of anilines to nitroalkanes. Organic and Biomolecular Chemistry, 2015, 13, 4289-4295.	1.5	48
43	Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. CKJ: Clinical Kidney Journal, 2015, 8, 199-201.	1.4	8
44	Identification of dabigatran etexilate major degradation pathways by liquid chromatography coupled to multi stage high-resolution mass spectrometry. RSC Advances, 2015, 5, 45068-45081.	1.7	8
45	Early Anti-Coagulation after Ischemic Stroke due to Atrial Fibrillation is Safe and Prevents Recurrent Stroke. Canadian Journal of Neurological Sciences, 2015, 42, 92-95.	0.3	6
46	Hypertension induced by chemotherapeutic and immunosuppressive agents: A new challenge. Critical Reviews in Oncology/Hematology, 2015, 93, 28-35.	2.0	40
47	A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate. Blood Coagulation and Fibrinolysis, 2016, 27, 563-567.	0.5	2
48	Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation. Annals of Pharmacotherapy, 2016, 50, 847-854.	0.9	11
49	Aminocaproic Acid and Tranexamic Acid Fail to Reverse Dabigatran-Induced Coagulopathy. American Journal of Therapeutics, 2016, 23, e1619-e1622.	0.5	6
50	Direct Oral Anticoagulants in Cirrhosis. Current Treatment Options in Gastroenterology, 2016, 14, 247-256.	0.3	35
51	Antithrombotic Drugs (Anticoagulants, Antiplatelets, and Thrombolytics)., 2016, , 383-412.		2
52	A Chromogenic and Fluorogenic Peptide Substrate for the Highly Sensitive Detection of Proteases in Biological Matrices. Journal of Medicinal Chemistry, 2016, 59, 7576-7583.	2.9	9
53	Drug Interactions of Direct-Acting Oral Anticoagulants. Drug Safety, 2016, 39, 841-845.	1.4	37
54	Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring. Clinical Toxicology, 2016, 54, 286-289.	0.8	8
55	Are New Oral Anticoagulants Safer Than Vitamin K Antagonists in the Treatment of Venous Thromboembolism?. Annals of Emergency Medicine, 2016, 67, 455-457.	0.3	1
56	Novel Oral Anticoagulants in the Peri-Endoscopic Period. Cardiology in Review, 2017, 25, 223-229.	0.6	0

#	ARTICLE	IF	CITATIONS
57	Direct acting oral anticoagulant: Bench to bedside. Medical Journal Armed Forces India, 2017, 73, 274-281.	0.3	0
58	Hemorrhage and Transfusions in the Surgical Patient. , 2017, , 145-158.		0
59	Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation. Journal of Cutaneous Medicine and Surgery, 2017, 21, 540-550.	0.6	15
60	Dual inhibition of HY023016 based on binding properties of platelet membrane receptor subunit glycoprotein Ibl± and thrombin exosites. European Journal of Pharmacology, 2018, 822, 51-58.	1.7	0
61	Direct Oral Anticoagulants. , 2018, , 87-103.		0
62	Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 859-866.	0.7	5
63	Management of the Trauma Patient on Direct Oral Anticoagulants. Current Anesthesiology Reports, 2018, 8, 107-118.	0.9	0
64	Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2018, 135, 231-235.	0.4	7
65	Approaches to prevent bleeding associated with anticoagulants: current status and recent developments. Drug Delivery and Translational Research, 2018, 8, 928-944.	3.0	18
68	Direct-Acting Oral Anticoagulants and Their Reversal Agentsâ€”An Update. Medicines (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.7	31
69	Periprocedural Anticoagulation Management For Nonoperating Room Anesthesia Procedures: A Clinical Guide. Seminars in Cardiothoracic and Vascular Anesthesia, 2019, 23, 352-368.	0.4	5
70	Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. Journal of Personalized Medicine, 2019, 9, 7.	1.1	80
71	<p>Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran</p>. Vascular Health and Risk Management, 2019, Volume 15, 139-142.	1.0	2
72	Deciphering the canonical blockade of activated Hageman factor (FXIIa) by benzamidine in the coagulation cascade: A thorough dynamical perspective. Chemical Biology and Drug Design, 2019, 94, 1905-1918.	1.5	2
73	Effectiveness and Safety of Nonâ€”Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation. Journal of the American Heart Association, 2019, 8, e011112.	1.6	54
74	Insight into the perioperative management of direct oral anticoagulants: concerns and considerations. Expert Opinion on Pharmacotherapy, 2019, 20, 465-472.	0.9	2
75	A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects. Drug Research, 2020, 70, 33-40.	0.7	2
76	A composite nanocarrier to inhibit precipitation of the weakly basic drug in the gastrointestinal tract. Drug Delivery, 2020, 27, 712-722.	2.5	3

#	ARTICLE	IF	CITATIONS
77	Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. <i>Advances in Therapy</i> , 2020, 37, 3537-3550.	1.3	16
78	Pharmacological Review of Anticoagulants. , 0, , .		2
79	Design, synthesis and biological activity evaluation of novel methyl substituted benzimidazole derivatives. <i>Tetrahedron</i> , 2020, 76, 131027.	1.0	11
80	Management of epistaxis in patients on novel oral anticoagulation therapy. <i>Journal of Laryngology and Otology</i> , 2020, 134, 316-322.	0.4	3
81	A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story. <i>Future Cardiology</i> , 2021, 17, 215-226.	0.5	2
82	Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. <i>Journal of Personalized Medicine</i> , 2021, 11, 37.	1.1	60
83	Bilateral Pulmonary Emboli on Dabigatran. <i>Cureus</i> , 2021, 13, e15737.	0.2	0
84	Optimal interruption time of dabigatran oral administration to ablation (O-A time) in patients with atrial fibrillation: Integrated analysis of 2 randomized controlled clinical trials. <i>Journal of Cardiology</i> , 2021, 77, 652-659.	0.8	4
85	Idarucizumab (PRAXBINDÂ®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).. <i>American Journal of Emergency Medicine</i> , 2021, 46, 800.e1-800.e3.	0.7	2
86	Atrial Fibrillation and Stroke Prevention. , 2015, , 261-276.		1
87	Dabigatran-Induced Acute Interstitial Nephritis: An Important Complication of Newer Oral Anticoagulation Agents. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 791-794.	0.6	15
88	A SIX YEAR DRUG UTILIZATION STUDY IN A TERTIARY HEALTHCARE SYSTEM: EMERGENCE OF NEWER ORAL ANTICOAGULANTS. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2019, 6, 676-679.	0.0	1
89	Benzimidazole: A Milestone in the Field of Medicinal Chemistry. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 532-565.	1.1	62
90	Newer Oral Anticoagulants: Stroke Prevention and Pitfalls. <i>Open Cardiovascular Medicine Journal</i> , 2016, 10, 94-104.	0.6	6
91	Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction. <i>Journal of Research in Medical Sciences</i> , 2017, 22, 19.	0.4	4
92	New indications for dabigatran: A suggestion from a drug use evaluation study. <i>Journal of Research in Pharmacy Practice</i> , 2017, 6, 211.	0.2	4
93	Temporal Trends and Patient Characteristics Associated With Drug Utilisation After First-Ever Stroke: Insights From Chronic Disease Registry Data in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 137-154.	0.2	3
94	Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function. <i>Clinical Nephrology Case Studies</i> , 2014, 2014, 1-5.	0.3	2

#	ARTICLE	IF	CITATIONS
95	Neurosurgical complications of direct thrombin inhibitorsâ€”catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. Yearbook of Neurology and Neurosurgery, 2012, 2012, 205-207.	0.0	0
96	Gastrointestinal bleeding due to marked coagulopathy from acute kidney injury in a patient taking dabigatran. Journal of the Japanese Society of Intensive Care Medicine, 2015, 22, 143-144.	0.0	0
97	Oral anticoagulants: Optimizing venous thromboembolism management. Journal of Applied Hematology, 2019, 10, 111.	0.1	0
98	Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting. Canadian Family Physician, 2014, 60, e535-40.	0.1	2
99	Atrial Fibrillation - A Common Ground for Neurology and Cardiology. Journal of Atrial Fibrillation, 2013, 6, 550.	0.5	0
100	Use of direct oral anticoagulants in ICU patients. Part I â€“ Applied pharmacology. Anaesthesiology Intensive Therapy, 2021, 53, 429-439.	0.4	3
101	Systemic Anticoagulation and Reversal. Surgical Clinics of North America, 2022, 102, 53-63.	0.5	1
103	Inhibition of fibrin clot formation. , 2022, , 121-130.		0
104	Peculiarities of dabigatran pharmacogenetics: literature review. Journal of Arrhythmology, 2022, 29, 39-44.	0.1	0
106	ãƒ¢ãƒ“ã, -ãƒˆãƒ ©ãƒ³ã†...æœäãç”ÿã•ãŸã°ƒç, ,ã²çµè...ç²~è†œã,ã†°è†œã«ã,ã^ã,šçµè...ã°œã...”æ~ã,’ã½ TMã,„€ã³ã•ã.€ãŸ1ã¾4< (A case of	0.0	0
107	Proximal femur fractures in patients taking anti-coagulants: has anything changed?. EFORT Open Reviews, 2022, 7, 356-364.	1.8	3
108	Delayed Concentration Effect Models for Dabigatran Anticoagulation. Paediatric Anaesthesia, 0, , .	0.6	2
109	Effect of Genotype on the Pharmacokinetics and Bleeding Events of Direct Oral Anticoagulants: A Systematic Review and Metaâ€“analysis. Journal of Clinical Pharmacology, 0, , .	1.0	0
110	An update on applications and limitations of direct oral anticoagulants. The Egyptian Journal of Internal Medicine, 2023, 35, .	0.3	0
113	Laboratory Monitoring of Direct Oral Anticoagulants. , 0, , .		0